<DOC>
	<DOCNO>NCT00305812</DOCNO>
	<brief_summary>RATIONALE : Lenalidomide may stop growth multiple myeloma block blood flow cancer . It may also stimulate immune system different way stop cancer cell grow . Drugs use chemotherapy , melphalan , work different way stop growth cancer cell , either kill cell stop divide . Giving lenalidomide together melphalan may kill cancer cell . PURPOSE : This randomized phase II trial study side effect best dose lenalidomide give together melphalan see well work treat patient multiple myeloma .</brief_summary>
	<brief_title>Lenalidomide Melphalan Treating Patients With Previously Untreated Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate tolerability 2 different dos lenalidomide administer melphalan patient previously untreated multiple myeloma planning undergo future autologous stem cell transplantation . Secondary - Characterize toxicity profile lenalidomide combination melphalan . - Determine tumor response patient 2 12 course induction therapy lenalidomide melphalan 6 month maintenance therapy dexamethasone . - Determine progression-free overall survival patient . - Determine time dose modification time dose discontinuation patient . Tertiary - Examine wnt pathway inhibition response lenalidomide pre- post-treatment bone marrow blood sample use enzyme-linked immunosorbent assay ( ELISA ) , gene expression profiling , drosophila-based chemical genetics , surface-enhanced laser desorption/ionization mass spectrometry ( SELDI MS ) proteomics . OUTLINE : This multicenter , randomize , open-label , dose-finding study lenalidomide . Prior randomization , 6 patient receive oral lenalidomide low dose ( dose use arm I ) daily day 1-21 oral melphalan daily day 1-4 . Treatment repeat every 28 day 3 course . If unacceptable toxicity occur , trial proceed randomization occur . - Induction therapy : Patients randomize 1 2 dose level lenalidomide . - Arm I : Patients receive oral lenalidomide daily day 1-21 oral melphalan daily day 1-4 . - Arm II : Patients receive oral lenalidomide arm I , low dose , melphalan arm I , high dose . Treatment arm repeat every 28 day 12 course absence disease progression unacceptable toxicity . After 12 course induction therapy , patient arm without progressive disease proceed maintenance therapy . - Maintenance therapy : Patients receive oral dexamethasone daily day 1-4 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 4 week every 2 month thereafter . PROJECTED ACCRUAL : A total 92 patient accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm multiple myeloma one following : Biopsy osteolytic lesion soft tissue tumor compose plasma cell Bone marrow aspirate and/or biopsy demonstrate ≥ 10 % plasmacytosis Bone marrow &lt; 10 % plasma cell ≥ 1 bony lesion AND meet Mprotein criterion Ineligible stem cell transplantation due following : Advanced age Comorbid illness Patient preference Previously untreated disease Measurable ( i.e. , quantifiable ) serum Mcomponent IgG , IgA , IgD , IgE initial diagnosis OR , lightchain disease present ( urine Mprotein ) , urinary excretion lightchain protein ( Bence Jones ) ≥ 1.0 g/24 hour initial diagnosis No nonsecretory myeloma PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 12 month Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 150,000/mm^3 Creatinine ≤ 3 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN AST and/or ALT ≤ 1.5 time ULN Alkaline phosphatase ≤ 1.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use 2 method effective contraception 4 week completion study treatment No malignancy within past 5 year , except adequately treat nonmelanoma skin cancer curatively treat situ cancer cervix No hypersensitivity thalidomide component , include development desquamate rash No serious illness medical condition would preclude study participation No history significant neurologic psychiatric disorder would preclude informed consent No known HIV positivity No preexist cardiovascular condition and/or symptomatic cardiac dysfunction , include follow : Significant cardiac event ( include symptomatic heart failure angina ) within 3 month prior randomization Any cardiac disease increase risk ventricular arrhythmia History ventricular arrhythmia symptomatic require treatment , include follow : Multifocal premature ventricular contraction Bigeminy Trigeminy Ventricular tachycardia/fibrillation/flutter/arrhythmia NOS PRIOR CONCURRENT THERAPY : No prior chemotherapy corticosteroid treatment multiple myeloma Prior corticosteroid treatment hypercalcemia spinal cord compression allow provide maximum level reach ( i.e. , &lt; 120 mg dexamethasone &lt; 792 mg prednisone ) Prior radiotherapy single sit pain control local plasmacytoma allow Prior concurrent bisphosphonates allow At least 28 day since prior investigational anticancer agent therapy No concurrent corticosteroids physiologic replacement dos Concurrent radiotherapy site active myeloma pain neurologic compromise allow No concurrent filgrastim ( GCSF ) day 1 course 1 No concurrent anticancer therapy No concurrent investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>